CD44 is expressed in a large number of mammalian cell types. The standard isoform, designated CD44s, comprising exons 1–5 and 16–20 is expressed in most cell types. CD44 splice variants containing variable exons are designated CD44v. Some epithelial cells also express a larger isoform (CD44E), which includes exons v8–10.
CD44 is a receptor for hyaluronic acid and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). CD44 function is controlled by its posttranslational modifications. One critical modification involves discrete sialofucosylations rendering the selectin-binding glycoform of CD44 called HCELL (for Hematopoietic Cell E-selectin/L-selectin Ligand). The HCELL glycoform was originally discovered on human hematopoietic stem cells and leukemic blasts, and was subsequently identified on cancer cells. HCELL functions as a "bone homing receptor", directing migration of human hematopoietic stem cells and mesenchymal stem cells to bone marrow. Ex vivo glycan engineering of the surface of live cells has been used to enforce HCELL expression on any cell that expresses CD44. CD44 glycosylation also directly controls its binding capacity to fibrin and immobilized fibrinogen.
This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumormetastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms; however, the full length nature of some of these variants has not been determined. Alternative splicing is the basis for the structural and functional diversity of this protein, and may be related to tumor metastasis. Splice variants of CD44 on colon cancer cells display sialofucosylated HCELL glycoforms that serve as P-, L-, and E-selectin ligands and fibrin, but not fibrinogen, receptors under hemodynamic flow conditions pertinent to the process of cancer metastasis. CD44 gene transcription is at least in part activated by beta-catenin and Wnt signalling (also linked to tumour development).
CD44 expression is an indicative marker for effector-memory T-cells. Memory cell proliferation (activation) can also be assayed in vitro with CFSE chemical tagging.
In addition, variations in CD44 are reported as cell surface markers for some breast and prostate cancer stem cells.In breast cancer research CD44+/CD24- expression is commonly used as a marker for breast CSCs and is used to sort breast cancer cells into a population enriched in cells with stem-like characteristics. and has been seen as an indicator of increased survival time in epithelialovarian cancer patients.
Endometrial cells in women with endometriosis demonstrate increased expression of splice variants of CD44, and increased adherence to peritoneal cells.
CD44 is a multistructural and multifunctional cell surface molecule involved in cell proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines, chemokynes, and growth factors to the corresponding receptors, and docking of proteases at the cell membrane, as well as in signaling for cell survival. All these biological properties are essential to the physiological activities of normal cells, but they are also associated with the pathologic activities of cancer cells. Experiments in animals have shown that targeting of CD44 by antibodies, antisense oligonucleotides, and CD44-soluble proteins markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential of anti-CD44 agents. Furthermore, because alternative splicing and posttranslational modifications generate many different CD44 sequences, including, perhaps, tumor-specific sequences, the production of anti-CD44 tumor-specific agents may be a realistic therapeutic approach. However, in many cancers (renal cancer and non-Hodgkin's lymphomas are exceptions), a high level of CD44 expression is not always associated with an unfavorable outcome. On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. Additionally, in many cases different research groups analyzing the same neoplastic disease reached contradictory conclusions regarding the correlation between CD44 expression and disease prognosis, possibly due to differences in methodology. These problems must be resolved before applying anti-CD44 therapy to human cancers.
^Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW, Anstee DJ (May 1988). "The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene". Immunology64 (1): 37–43. PMC1385183. PMID2454887.
^Burdick MM, Chu JT, Godar S, Sackstein R (May 2006). "HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells". J. Biol. Chem.281 (20): 13899–905. doi:10.1074/jbc.M513617200. PMID16565092.
^ abHanley WD, Napier SL, Burdick MM, Schnaar RL, Sackstein R, Konstantopoulos K. (Dec 2005). "Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells". FASEB J20 (2): 337–9. doi:10.1096/fj.05-4574fje. PMID16352650.
^ abNapier SL, Healy ZR, Schnaar RL, Konstantopoulos K (Feb 2007). "Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells: the roles of CD44v and alternative sialofucosylated selectin ligands". J Biol Chem282 (6): 3433–41. doi:10.1074/jbc.M607219200. PMID17135256.
^ abThomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K (Jun 2008). "Carcinoembryonic Antigen and CD44 Variant Isoforms Cooperate to Mediate Colon Carcinoma Cell Adhesion to E- and L-selectin in Shear Flow". J Biol Chem283 (23): 15647–55. doi:10.1074/jbc.M800543200. PMC2414264. PMID18375392.
^ abAlves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K (Apr 2008). "The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion". Am J Physiol Cell Physiol294 (4): C907–16. doi:10.1152/ajpcell.00463.2007. PMID18234849.
^ abAlves CS, Yakovlev S, Medved L, Konstantopoulos K (Jan 2009). "Biomolecular Characterization of CD44-Fibrin(ogen) Binding: DISTINCT MOLECULAR REQUIREMENTS MEDIATE BINDING OF STANDARD AND VARIANT ISOFORMS OF CD44 TO IMMOBILIZED FIBRIN(OGEN)". J Biol Chem284 (2): 1177–89. doi:10.1074/jbc.M805144200. PMC2613610. PMID19004834.
^Griffith JS, Liu YG, Tekmal RR, Binkley PA, Holden AE, Schenken RS (April 2010). "Menstrual Endometrial Cells from Women with Endometriosis Demonstrate Increased Adherence to Peritoneal Cells and Increased Expression of CD44 Splice Variants". Fertil. Steril.93 (6): 1745–9. doi:10.1016/j.fertnstert.2008.12.012. PMC2864724. PMID19200980.
^Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY (August 2009). "CD44 variant isoforms in head and neck squamous cell carcinoma progression". Laryngoscope119 (8): 1518–30. doi:10.1002/lary.20506. PMC2718060. PMID19507218.
^Assimakopoulos D, Kolettas E, Patrikakos G, Evangelou A (October 2002). "The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas". Histol. Histopathol.17 (4): 1269–81. PMID12371152.
^Naor, David et al. "CD44 in cancer.". Critical reviews in clinical laboratory sciences 39.6 (2002): 527-579.
^Bourguignon LY, Singleton PA, Zhu H, Diedrich F (August 2003). "Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression". J. Biol. Chem.278 (32): 29420–34. doi:10.1074/jbc.M301885200. PMID12748184.
^ abIlangumaran S, Briol A, Hoessli DC (May 1998). "CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes". Blood91 (10): 3901–8. PMID9573028.
^Taher TE, Smit L, Griffioen AW, Schilder-Tol EJ, Borst J, Pals ST (February 1996). "Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes". J. Biol. Chem.271 (5): 2863–7. doi:10.1074/jbc.271.5.2863. PMID8576267.
^Bourguignon LY, Zhu H, Shao L, Chen YW (March 2001). "CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration". J. Biol. Chem.276 (10): 7327–36. doi:10.1074/jbc.M006498200. PMID11084024.